BioSpace News Archive

Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 PANOVA-3 clinical trial evaluating the safety and efficacy of Tumor Treating Fields (TTFields) therapy together with nab-paclitaxel and gemcitabine for the treatment of patients with unresectable, locally advanced pancreatic cancer.

Cisplatin is a widely used chemotherapy drug for various types of cancers. However, frequent usage can lead to the development of drug resistance and neuropathic pain, eventually resulting in treatment failure.

Ipsen (Euronext: IPN: ADR: IPSEY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Bylvay® (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) aged six months or older.

PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company”), an intellectual property driven biotechnology company focused upon discovery and development of novel, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health

SunHo BioPharmaceutical Co., Ltd. (“SunHo”) announced that IBB0979 (B7H3-IL10 immunocytokine), a potential first-in-class immunocytokine developed in-house for the treatment of locally advanced or metastatic solid tumors has entered Phase I/II clinical trials.

IntelGenx Technologies Corp. announces the resignation of Mr. J. Bernard Boudreau from the Board of Directors of the Company.

YS Biopharma Co., Ltd. (NASDAQ: YS) (“YS Biopharma” or the “Company”) today announced that it plans to release its financial results for the fiscal year ended March 31, 2023 after the U.S. market closes on Wednesday, July 26, 2023.

Coherus BioSciences, Inc., announced that effective July 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 187,000 shares of the common stock of the Company to newly hired employees with a per share exercise price of $4.17, the closing trading price on the grant date.

The U.S. Food and Drug Administration is working closely with Pfizer to assess the impact of the damage at Pfizer’s Rocky Mount, North Carolina, facility.

Molecure completes successful Secondary Public Offering (SPO) of approximately PLN50 million (USD12 million) with proceeds to be used to fund and build a first in class, sustainable pipeline of break through therapies